EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY 4.0

Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial

Anna Maria Di Giacomo, Vanna Chiarion-Sileni, Michele Del Vecchio, Pier Francesco Ferrucci, Michele Guida, Pietro Quaglino, Massimo Guidoboni, Paolo Marchetti, Elena Simonetti, Federica Santangelo, Giovanni Amato, Alessia Covre und 6 weitere

European Journal of Cancer · 2024

DOI: 10.1016/j.ejca.2024.113531 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Anna Maria Di Giacomo und 17 weiteren Autor:innen. Beteiligte Einrichtung: University of Siena, Siena, Italy; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Sie…. Hauptthemen laut MEDLINE: Brain Neoplasms, Melanoma, Nitrosourea Compounds, Organophosphorus Compounds. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The primary analysis of the phase III NIBIT-M2 study showed a 41% 4-year overall survival (OS) of melanoma patients with asymptomatic brain metastases treated with ipilimumab plus nivolumab. METHODS: Here, we report the 7-year efficacy outcomes and the Health-Related Quality of Life (HRQoL) analyses of the NIBIT-M2 study. RESULTS: As of May 1, 2023, at a median follow-up of 67 months (mo), the median OS was 8.5 (95% CI: 6.6-10.3), 8.2 (95% CI: 2.1-14.3) and 29.2 (95% CI: 0-69.9) mo for the fotemustine (F) Arm A, ipilimumab plus fotemustine Arm B, and ipilimumab plus nivolumab Arm C, respectively. The 7-year OS rate was 10.0% (95% CI: 0-22.5) in Arm A, 10.3% (95% CI: 0-22.6) in Arm B, and 42.8% (95% CI: 23.4-62.2) in Arm C. HRQoL was preserved in all treatment arms. Most functional scales evaluated from baseline to W12 were preserved, with a lower mean score decrease for EORTC Quality of Life Questionnaire (QLQ)-C30 and an increase for EORTC QLQ-Brain neoplasm (BN20) in patients receiving ipilimumab plus nivolumab. CONCLUSIONS: With the longest follow-up available to date in melanoma patients with asymptomatic brain metastases, the NIBIT-M2 study continues to show persistent therapeutic efficacy of I ipilimumab plus nivolumab while preserving HRQoL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain NeoplasmsMelanomaNitrosourea CompoundsOrganophosphorus CompoundsHumansAntineoplastic Combined Chemotherapy ProtocolsIpilimumabNivolumabQuality of Life

Stichwörter der Autor:innen

Brain metastasesHealth-Related Quality of Life (HRQoL)IpilimumabLong-term survivalMelanomaNivolumab

Substanzen

fotemustineIpilimumabNitrosourea CompoundsNivolumabOrganophosphorus Compounds

Autor:innen und Institutionen

  • University of Siena, Siena, Italy; Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Siena, Italy; NIBIT Foundation Onlus, Italy. Electronic address: a…
  • Melanoma Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
  • Unit of Melanoma, Medical Oncology, Department of Medical Oncology and Hematology, Istituto Nazionale dei Tumori, Milan, Italy.
  • Department of Oncology Gruppo Multimedica, Milan, Italy.
  • Rare Tumors and Melanoma Unit, IRCCS Istituto Tumori "Giovanni Paolo II", Bari, Italy.
  • Dermatology Clinic, Department of Medical Science, University of Turin, Italy.

Zitieren

APA

Di Giacomo, A. M., Chiarion-Sileni, V., Del Vecchio, M., Ferrucci, P. F., Guida, M., Quaglino, P., Guidoboni, M., Marchetti, P., Simonetti, E., Santangelo, F., Amato, G., Covre, A., Camerini, R., Valente, M., Mandalà, M., Giannarelli, D., Calabrò, L., & Maio, M. (2024). Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.113531

Vancouver

Di Giacomo AM, Chiarion-Sileni V, Del Vecchio M, Ferrucci PF, Guida M, Quaglino P, et al. Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.113531

BibTeX
@article{DiGiacomo2024,
  author = {Di Giacomo, Anna Maria and Chiarion-Sileni, Vanna and Del Vecchio, Michele and Ferrucci, Pier Francesco and Guida, Michele and Quaglino, Pietro and Guidoboni, Massimo and Marchetti, Paolo and Simonetti, Elena and Santangelo, Federica and Amato, Giovanni and Covre, Alessia and Camerini, Roberto and Valente, Monica and Mandalà, Mario and Giannarelli, Diana and Calabrò, Luana and Maio, Michele},
  title = {Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial},
  journal = {European Journal of Cancer},
  year = {2024},
  doi = {10.1016/j.ejca.2024.113531}
}
Kostenlos starten →